Analyst Information

 

Yasmeen Rahimi, Ph.D.

Sr. Research Analyst

Yasmeen Rahimi, Ph.D.

Yasmeen Rahimi is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in July 2020, Rahimi was a senior research analyst and co-head of biotechnology equity research team at ROTH Capital Partners. Before that, she worked as an equity research associate at H.C. Wainwright & Co. and Guggenheim Securities. Prior to making the transition to Wall Street, Rahimi was a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of rare disease programs; she has an extensive expertise in liver metabolism. Rahimi trained as a postdoctoral fellow at Yale University in the laboratory of Gerald Shulman after completing her Ph.D. from Indiana University School of Medicine. In addition, she has a M.S. in Bioanalytical Chemistry from Purdue University and a joint B.A. in German and Chemistry from Butler University.

Associates:

Paul O'Brien
Rachel Yang
Universe Coverage:
Healthcare:   Biotechnology
ETNB89bio, Inc.
ALBOAlbireo Pharma, Inc.
ALTAltimmune, Inc.
AXLAAxcella Health, Inc.
CBAYCymaBay Therapeutics Inc.
ICPTIntercept Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals, Inc.
NGMNGM Biopharmaceuticals, Inc.